Stocks and Investing
Stocks and Investing
Thu, March 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yanan Zhu Maintained (BEAM) at Buy with Decreased Target to $105 on, Mar 1st, 2023
Yanan Zhu of Wells Fargo, Maintained "Beam Therapeutics Inc." (BEAM) at Buy with Decreased Target from $125 to $105 on, Mar 1st, 2023.
Yanan has made no other calls on BEAM in the last 4 months.
There are 5 other peers that have a rating on BEAM. Out of the 5 peers that are also analyzing BEAM, 1 agrees with Yanan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Maintained at Hold with Decreased Target to $53 on, Tuesday, November 8th, 2022
These are the ratings of the 4 analyists that currently disagree with Yanan
- Rick Bienkowski of "Cantor Fitzgerald" Initiated at Buy and Held Target at $62 on, Wednesday, February 1st, 2023
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $77 on, Monday, January 23rd, 2023
- Kostas Biliouris of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $66 on, Tuesday, December 20th, 2022
- Samantha Semenkow of "Citigroup" Initiated at Strong Buy and Held Target at $62 on, Tuesday, December 13th, 2022
Contributing Sources